Natural Systems Multi Vitamin Recalled for Low Magnesium Content
FDA analysis found Natural Systems Naturasys Multi Vitamin contains magnesium at only 33.5% of the labeled amount. The recall affects 554 bottles with lot 38883 (expires 07/2024).
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall involving inadequate potency of a micronutrient. No illnesses or injuries have been reported. The hazard is underdosage rather than contamination or direct harm. Per the severity rubric, Class III recalls are typically scored 1-2; with no reported adverse events and a theoretical hazard, this scores as Moderate (2).
Plain-English summary
Natural Systems Naturasys Multi Vitamin High Potency Dietary Supplement, 60 tablets per bottle, is subject to recall. FDA laboratory analysis found the magnesium content in the product is only 33.5% of the amount declared on the label.
The affected product is identified by Lot 38883 with expiration date 07/2024. A total of 554 bottles have been distributed domestically and internationally.
The recalled product
- Product
- Natural Systems, Naturasys MULTI VITAMIN HIGH POTENCY AND FORMULATION, Dietary Supplement 60 Tablets
- Manufacturer
- Emceta International Inc.
- Category
- Drug — Dietary Supplement
- Hazard
- mis-labeling
- under-dosage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 38883
- Exp. 07/2024
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27